Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer

Kato, Jun; Nagahara, Akihito; Kodani, Tomohiro

doi:10.4172/2165-7092.1000102

Cited by 4 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that vaccination with KIF20A and VEGFR1 epitope peptides was safe and feasible for the treatment of patients with advanced pancreatic cancer (6). In 2010, Masuzawa et al reported the results of a phase I/II clinical trial in which the safety of vaccination with VEGFR1 and VEGFR2 peptide combined with S-1 and cisplatin was demonstrated in patients with advanced gastric cancer (21).…”

Section: Discussionmentioning

confidence: 99%

“…Clinical trials are now underway to evaluate the safety and efficacy of the vaccination for the treatment of malignant melanoma and cancers of lung, kidney, pancreas, bile duct, colon and esophagus ( 5 , 17 – 20 ). We previously reported that vaccination with KIF20A and VEGFR1 epitope peptides was safe and feasible for the treatment of patients with advanced pancreatic cancer ( 6 ). In 2010, Masuzawa et al reported the results of a phase I/II clinical trial in which the safety of vaccination with VEGFR1 and VEGFR2 peptide combined with S-1 and cisplatin was demonstrated in patients with advanced gastric cancer ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

“…In many of the clinical cancer vaccine trials, maximum tolerated dose (MTD) has not been observed. Many kinds of peptides which were employed in previous studies had a fixed dose ( 5 , 6 , 22 ). Further, dose escalation was not recognized in a previous colon cancer trial ( 23 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Higashihara

Kato

Nagahara

et al. 2013

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

Peptide vaccine treatment has attracted attention in recent years as a new therapy option for chemotherapy-resistant, advanced, unresectable cancer. The safety of peptide vaccination with HLA-A*2402-restricted URLC10-A24-177 and VEGFR1-A12-9 1084 epitope peptides (fixed 2-mg dose) was investigated in a phase I clinical trial of patients with advanced gastric cancer who were refractory to chemotherapy. We determined the HLA genotype of the subjects after enrollment, results of which were held by the evaluation committee and kept from both patients and investigators until completion of the study. The primary end-point was safety of the peptide vaccination. The secondary end-points were immunological responses and clinical outcome, which were compared between the HLA-A*2402-positive and HLA-A*2402-negative groups. The peptides were subcutaneously administered on day 1, 8, 15 and 22 within a 28-day treatment cycle. A total of 14 patients was enrolled in this study; 12 of the 14 patients received 4 or more vaccinations (at least 1 course). No patient had a severe treatment-related adverse event. Findings from evaluation of clinical responses after a single course showed that 4 cases had stable disease and 8 cases had progressive disease. The median overall survival time (MST) for the 12 patients was 3.9 months. The MSTs in the HLA-A*2402-positive and HLA-A*2402-negative groups were, 4.2 and 3.6 months (p= 0.9164), respectively. The results of this study showed that vaccination with URLC10 and VEGFR1 peptides was a safe treatment for advanced gastric cancer. This trial was registered with University Hospital Medical Information Network (UMIN, no. 000002409).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Higashihara

Kato

Nagahara

et al. 2013

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Immunoinformatics Prediction of Epitope Based Peptide Vaccine Against Mycobacterium Tuberculosis PPE65 family Protein

Elhag

Sati²,

Saadaldin

et al. 2019

Preprint

View full text Add to dashboard Cite

Introduction: Tuberculosis (TB) is a serious disease with varying rates of mortality and morbidity among infected individuals which estimates for approximately two million deaths/year. The number of deaths could increase by 60% if left untreated. It mainly affects immune-compromised individuals and people of third world, due to poverty, low health standards, and inadequate medical care. It has varying range of manifestations that is affected by the host immune system response, the strain causing the infection, its virulence, and transmissibility. Materials and methods: A total of 1750 Mycobacterium Tuberculosis PPE65 family protein strains were retrieved from National Center for Biotechnology Information (NCBI) database on March 2019 and several tools were used for the analysis of the T-and B-cell peptides and homology modelling. Results and conclusion: Four strong epitope candidates had been predicted in this study for having good binding affinity to HLA alleles, good global population coverage percentages. These peptides are YAGPGSGPM, AELDASVAM, GRAFNNFAAPRYGFK and a single B-cell peptide YAGP. This study uses immunoinformatics approach for the design of peptide based vaccines for M. tuberculosis. Peptide based vaccines are safer, more stable and less hazardous/allergenic when compared to conventional vaccines. In addition, peptide vaccines are less labouring, time consuming and cost efficient. The only weakness is the need to introduce an adjuvant to increase immunogenic stimulation of the vaccine recipient.

show abstract

消化器がんに対するがんペプチドワクチン療法

2013

Juntendo Medical Journal

View full text Add to dashboard Cite

Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer

Cited by 4 publications

References 44 publications

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Immunoinformatics Prediction of Epitope Based Peptide Vaccine Against Mycobacterium Tuberculosis PPE65 family Protein

消化器がんに対するがんペプチドワクチン療法

Contact Info

Product

Resources

About